Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage R&D toward its Dravet syndrome program. The asset in question, dubbed ...
Encoded Therapeutics is joining the ranks of biotechs pummeled by the whiplash of a difficult biotech market, laying off "close to 10%" of its team, according to Chief Business Officer David McNinch.
Strange happenings are occurring on Nessus. And, naturally, it’s up to the Guardian to unravel the source of these secrets. To that end, we’ll need to follow our lead to the Well of Echoes in Nessus.
ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that ...
AAV9-based Angelman Syndrome candidate, ETX201, demonstrates safety and target engagement in non-human primates (NHPs), with unsilencing of UBE3A across disease-relevant brain regions Multiple ...
Forty trillion is the kind of number that gives one pause. Consider it written out with its 13 zeros: 40,000,000,000,000. Assembling and maintaining a collection of 40 trillion of anything seems like ...
Charnita is a wife, pet mom, tech enthusiast, and part-time freelance writer with over 14 years of experience. She's done countless app roundups, product reviews, and tutorials! In her free time, she ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback